Why the study?
Does BQ-123 mitigate the acute systemic and renal effects of exogenous Angiotensin II in healthy male subjects?
Population
10 healthy male subjects
Comparison
BQ-123 (60 microg min IV), a specific… vs Placebo administered during the same stepwise…
Design
RCT, randomized, two-way cross-over, double blind
Follow-up
acute (15 min per dose level)
Authors
Loading...
ETA blockade does not mitigate acute Ang II renal or systemic effects; indicates these responses are independent of ET-1 release.
Does BQ-123 mitigate the acute systemic and renal effects of exogenous Angiotensin II in healthy male subjects?
Endothelin ETA-receptor blockade does not mitigate the acute systemic and renal pressor effects of exogenous Angiotensin II in humans, suggesting these effects are not mediated by acute ET-1 release.
Bayerle‐Eder et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: